TY - JOUR
T1 - Incidence of diabetes after cancer development a Korean national cohort study
AU - Hwangbo, Yul
AU - Kang, Danbee
AU - Kang, Minwoong
AU - Kim, Saemina
AU - Lee, Eun Kyung
AU - Kim, Young Ae
AU - Chang, Yoon Jung
AU - Choi, Kui Son
AU - Jung, So Youn
AU - Woo, Sang Myung
AU - Ahn, Jin Seok
AU - Sim, Sung Hoon
AU - Hong, Yun Soo
AU - Pastor-Barriuso, Roberto
AU - Guallar, Eliseo
AU - Lee, Eun Sook
AU - Kong, Sun Young
AU - Cho, Juhee
N1 - Publisher Copyright:
© 2018 American Medical Association. All rights reserved.
PY - 2018/8
Y1 - 2018/8
N2 - IMPORTANCE Diabetes is an established risk factor for developing cancer. A limited body of evidence also suggests that cancer can increase the risk of developing new cases of diabetes, but the evidence is inconclusive. OBJECTIVE To evaluate whether the development of cancer is associated with increasing risk of subsequent diabetes. DESIGN, SETTING, AND PARTICIPANTS This cohort study included a nationally representative sample of the Korean general population observed for up to 10 years (January 1, 2003, to December 31, 2013). A total of 524 089 men and women 20 to 70 years of age without diabetes and with no history of cancer at baseline were included. EXPOSURES Incident cancer (time-varying exposure). MAIN OUTCOMES AND MEASURES Incident type 2 diabetes using insurance claim codes. RESULTS During 3 492 935.6 person-years of follow-up (median follow-up, 7.0 years) in 494 189 individuals (50.0% female; mean [SD] age, 41.8 [12.5] years), 15 130 participants developed cancer and 26 610 participants developed diabetes. After adjustment for age, sex, precancer diabetes risk factors, metabolic factors, and comorbidities, the hazard ratio (HR) for diabetes associated with cancer development was 1.35 (95% CI, 1.26-1.45; P < .001). The excess risk for diabetes was highest in the first 2 years after cancer diagnosis, but it remained elevated throughout follow-up. By cancer type, development of pancreatic (HR, 5.15; 95% CI, 3.32-7.99), kidney (HR, 2.06; 95% CI, 1.34-3.16), liver (HR, 1.95; 95% CI, 1.50-2.54), gallbladder (HR, 1.79; 95% CI, 1.08-2.98), lung (HR, 1.74; 95% CI, 1.34-2.24), blood (HR, 1.61; 95% CI, 1.07-2.43), breast (HR, 1.60; 95% CI, 1.27-2.01), stomach (HR, 1.35; 95% CI, 1.16-1.58), and thyroid cancer (HR, 1.33; 95% CI, 1.12-1.59) was associated with a significantly increased risk of diabetes. CONCLUSIONS AND RELEVANCE In this large Korean cohort, cancer development increased the risk of subsequent diabetes. These data provide evidence that cancer is associated with an increased risk of diabetes in cancer survivors independent of traditional diabetes risk factors. Physicians should remember that patients with cancer develop other clinical problems, such as diabetes, with higher frequency than individuals without cancer, and should consider routine diabetes screening in these patients.
AB - IMPORTANCE Diabetes is an established risk factor for developing cancer. A limited body of evidence also suggests that cancer can increase the risk of developing new cases of diabetes, but the evidence is inconclusive. OBJECTIVE To evaluate whether the development of cancer is associated with increasing risk of subsequent diabetes. DESIGN, SETTING, AND PARTICIPANTS This cohort study included a nationally representative sample of the Korean general population observed for up to 10 years (January 1, 2003, to December 31, 2013). A total of 524 089 men and women 20 to 70 years of age without diabetes and with no history of cancer at baseline were included. EXPOSURES Incident cancer (time-varying exposure). MAIN OUTCOMES AND MEASURES Incident type 2 diabetes using insurance claim codes. RESULTS During 3 492 935.6 person-years of follow-up (median follow-up, 7.0 years) in 494 189 individuals (50.0% female; mean [SD] age, 41.8 [12.5] years), 15 130 participants developed cancer and 26 610 participants developed diabetes. After adjustment for age, sex, precancer diabetes risk factors, metabolic factors, and comorbidities, the hazard ratio (HR) for diabetes associated with cancer development was 1.35 (95% CI, 1.26-1.45; P < .001). The excess risk for diabetes was highest in the first 2 years after cancer diagnosis, but it remained elevated throughout follow-up. By cancer type, development of pancreatic (HR, 5.15; 95% CI, 3.32-7.99), kidney (HR, 2.06; 95% CI, 1.34-3.16), liver (HR, 1.95; 95% CI, 1.50-2.54), gallbladder (HR, 1.79; 95% CI, 1.08-2.98), lung (HR, 1.74; 95% CI, 1.34-2.24), blood (HR, 1.61; 95% CI, 1.07-2.43), breast (HR, 1.60; 95% CI, 1.27-2.01), stomach (HR, 1.35; 95% CI, 1.16-1.58), and thyroid cancer (HR, 1.33; 95% CI, 1.12-1.59) was associated with a significantly increased risk of diabetes. CONCLUSIONS AND RELEVANCE In this large Korean cohort, cancer development increased the risk of subsequent diabetes. These data provide evidence that cancer is associated with an increased risk of diabetes in cancer survivors independent of traditional diabetes risk factors. Physicians should remember that patients with cancer develop other clinical problems, such as diabetes, with higher frequency than individuals without cancer, and should consider routine diabetes screening in these patients.
UR - http://www.scopus.com/inward/record.url?scp=85051439839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051439839&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2018.1684
DO - 10.1001/jamaoncol.2018.1684
M3 - Article
C2 - 29879271
AN - SCOPUS:85051439839
SN - 2374-2437
VL - 4
SP - 1099
EP - 1105
JO - JAMA Oncology
JF - JAMA Oncology
IS - 8
ER -